Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibitors: a tsunami of indications in different malignancies.

Pharmacogenomics - 1 Feb 2020

Haddad Gaëlle, Saadé Marie Christelle, Eid Roland, Haddad Fady Gh, Kourie Hampig Raphael

Abstract excerpt

The evolution of precision medicine in the field of oncology has led to a radical change in the course of malignancies. PARP inhibitors are drugs that block the activity of the PARP enzyme responsible for base excision repair and have shown significant positive response when used for tumors lacking homologous recombination, namely high efficacy among BRCA-mutated tumors. Since 2014, when olaparib received an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Repair

Share to Drug Approval

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Precision Medicine

Share to Survival Analysis

Source

Identifiers

PMID: 31967513
DOI: 10.2217/pgs-2019-0113

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitors: a tsunami of indications in different malignancies.PMID 31967513Read ↗

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current statusSemantic proximity Read ↗

An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer TherapySemantic proximity Read ↗

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancersSemantic proximity Read ↗

A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitorsSemantic proximity Read ↗

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancerSemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: A ReviewSemantic proximity Read ↗

A review on mechanisms of resistance to PARP inhibitorsSemantic proximity Read ↗

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA MutationsSemantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

[Cancer therapy by PARP inhibitors].Semantic proximity Read ↗

PARP Inhibitors for Cancer Therapy.Semantic proximity Read ↗

An Overview of PARP Inhibitors for the Treatment of Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.